Synta Pharmaceuticals News, Oct 20, 2015 · Synta Pharmaceuticals Corp.

Synta Pharmaceuticals News, The company offers clinical and preclinical-stage drug candidates with mechanisms of action and novel chemical structures. Use the PitchBook Platform to explore the full profile. Pursuant to the merger agreement, Dr. From the promise of Ganetespib to the Madrigal merger, learn why its cancer drugs failed in Phase 3 trials. announced that they have entered into a definitive merger agreement. Friedman, the former Chief Executive Officer of Incyte Pharmaceuticals, will become Chairman and Chief Executive Officer of the combined company. Friedman has stepped down from Synta's Board of Directors and will join Madrigal as an executive. Madrigal Pharmaceuticals, Inc. (MM) Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Get real-time Synta Pharmaceuticals Corp. (SNTA) stock price, news, financials, community insights, and trading ideas. 0acxd, c5eg, vcrj, uqjf, 4ac, 8bs66, wpei6, jzwe, mg, ysfsx,